Replies to post #154155 on Biotech Values

[JJM760]

Andy, I respectfully disagree with you and Peter. I believe that the market reaction was simply a continuation of the sell the news that has become the norm in biotech. With first year projections from Ariad at $50 mil, I think the surprise will be to the upside (and in a significant way!).

One can definitely argue that the $4 bil MC was bloated to begin with. However, a 20% haircut on early approval even with the black box label was overdone, IMO.

One thing is for sure, I am getting real tired of holding through approvals and getting the rug pulled out from me.

[DewDiligence]

I agree with Peter. The label will dissuade some oncologists from prescribing the drug second line.

If this happens to a material degree, ARIA should hire better sales reps.